Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors' reply. - Suppr

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors' reply.

作者信息

Narula N, Reinisch W

机构信息

Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

出版信息

Aliment Pharmacol Ther. 2016 Oct;44(7):772-3. doi: 10.1111/apt.13768.

DOI:10.1111/apt.13768

PMID:27593431

Abstract

摘要

相似文献

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors' reply.

Aliment Pharmacol Ther. 2016 Oct;44(7):772-3. doi: 10.1111/apt.13768.

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?

Aliment Pharmacol Ther. 2016 Oct;44(7):771-2. doi: 10.1111/apt.13743.

Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.

Aliment Pharmacol Ther. 2017 Mar;45(6):856-857. doi: 10.1111/apt.13968.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Cochrane Database Syst Rev. 2008 Jan 23(1):CD006893. doi: 10.1002/14651858.CD006893.

Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort.

Aliment Pharmacol Ther. 2017 Mar;45(6):855-856. doi: 10.1111/apt.13929.

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.

Aliment Pharmacol Ther. 2012 Jun;35(12):1397-407. doi: 10.1111/j.1365-2036.2012.05100.x. Epub 2012 Apr 22.

Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.

Aliment Pharmacol Ther. 2017 Jan;45(1):178-179. doi: 10.1111/apt.13842.

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.

Aliment Pharmacol Ther. 2010 Nov;32(10):1228-39. doi: 10.1111/j.1365-2036.2010.04466.x. Epub 2010 Sep 28.

Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.

BioDrugs. 2010 Dec 14;24 Suppl 1:25-7. doi: 10.2165/11586210-000000000-00000.

Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.

Eur J Gastroenterol Hepatol. 2013 Aug;25(8):885-91. doi: 10.1097/MEG.0b013e32836220ab.

引用本文的文献

Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview.

Medicina (Kaunas). 2022 Apr 21;58(5):567. doi: 10.3390/medicina58050567.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验